文献速递胸部肿瘤放疗姑息放疗与转移瘤

免疫治疗时代广泛期小细胞肺癌的巩固性胸部放疗:系统综述与荟萃分析

Consolidative thoracic radiotherapy in the immunotherapy era for extensive-stage small cell lung cancer: a systematic review and meta-analysis with emphasis on brain and liver metastases.
PubMed 文献 · Radiother Oncol · 2025-12-11

该系统综述与荟萃分析纳入20项研究共5282例接受化疗免疫治疗的广泛期小细胞肺癌患者,评估巩固性胸部放疗的疗效与安全性。结果显示巩固性胸部放疗可改善总生存和无进展生存,在基线脑转移患者中同样获益,但基线肝转移患者无改善,且可延长脑转移无进展生存,安全性可接受。

要点

  • 巩固性胸部放疗联合化疗免疫治疗改善广泛期小细胞肺癌患者的总生存和无进展生存。
  • 基线脑转移患者可从巩固性胸部放疗中获得总生存和无进展生存获益,肝转移患者无改善。
  • 巩固性胸部放疗延长脑转移无进展生存,≥3级肺炎和食管炎发生率分别为3.86%和1.27%。

核心结论

  • 在广泛期小细胞肺癌化疗免疫治疗人群中,巩固性胸部放疗显著改善总生存和无进展生存。
  • 基线脑转移患者可从巩固性胸部放疗中获益,而基线肝转移患者未见改善。
  • 巩固性胸部放疗可能延长脑转移无进展生存,安全性可接受。

研究设计与样本

  • 按PRISMA指南开展系统综述与配对荟萃分析,检索PubMed、Embase和Scopus至2025年9月1日。
  • 共纳入20项研究、5282例接受化疗免疫治疗的广泛期小细胞肺癌患者。

主要发现

  • 巩固性胸部放疗联合化疗免疫治疗改善总生存(HR 0.57,95%CI 0.48-0.66,p<0.001)。
  • 巩固性胸部放疗联合化疗免疫治疗改善无进展生存(HR 0.53,95%CI 0.45-0.63,p<0.001)。
  • 基线脑转移患者总生存改善(HR 0.57,95%CI 0.39-0.84,p=0.01),无进展生存改善(HR 0.42,95%CI 0.28-0.64,p<0.001)。
  • 基线肝转移患者未见改善。
  • 巩固性胸部放疗延长脑转移无进展生存(HR 0.46,95%CI 0.33-0.64,p<0.001)。

关键数值与推荐

  • 总生存HR 0.57(95%CI 0.48-0.66,p<0.001)。
  • 无进展生存HR 0.53(95%CI 0.45-0.63,p<0.001)。
  • 基线脑转移患者总生存HR 0.57(95%CI 0.39-0.84,p=0.01),无进展生存HR 0.42(95%CI 0.28-0.64,p<0.001)。
  • 脑转移无进展生存HR 0.46(95%CI 0.33-0.64,p<0.001)。
  • ≥3级肺炎发生率3.86%,≥3级食管炎发生率1.27%。

临床怎么用

  • 对接受化疗免疫治疗的广泛期小细胞肺癌患者,可考虑巩固性胸部放疗以改善生存。
  • 基线脑转移患者可能从巩固性胸部放疗中获益,基线肝转移患者需个体化评估。
  • 巩固性胸部放疗时需关注≥3级肺炎和食管炎风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Immunotherapy has redefined the therapeutic paradigm in extensive-stage small cell lung cancer (ES-SCLC). However, the potential role of consolidative thoracic radiotherapy (cTRT) in this context remains unresolved. This study evaluated the efficacy and safety of cTRT in patients with ES-SCLC treated with chemoimmunotherapy, with particular focus on patients with baseline liver and brain metastasis. METHODS: A systematic review and pairwise meta-analysis were conducted per PRISMA guidelines, including studies from PubMed, Embase, and Scopus up to September 1, 2025. Outcomes were reported as hazard ratios (HR) for overall survival (OS), progression-free survival (PFS), and brain metastasis-free survival (BMFS), and odds ratios (OR) for treatment-related adverse events (TRAEs) with 95 % confidence intervals (95 % CI). RESULTS: Twenty studies involving 5282 patients were included. cTRT combined with chemoimmunotherapy improved OS (HR: 0.57, 95 %CI: 0.48-0.66, p < 0.001) and PFS (HR: 0.53, 95 %CI: 0.45-0.63, p < 0.001). In patients with baseline brain metastasis, cTRT improved both OS (HR:0.57, 95 %CI: 0.39-0.84, p = 0.01) and PFS (HR:0.42, 95 %CI: 0.28-0.64, p < 0.001), whereas in patients with liver metastasis, there was no improvement. Furthermore, cTRT increased BMFS (HR: 0.46, 95 %CI: 0.33-0.64, p < 0.001). Grade ≥ 3 pneumonitis and esophagitis were observed in 3.86 % and 1.27 % of cTRT patients, respectively. CONCLUSIONS: cTRT confers significant improvements in OS and PFS in the general population of patients with ES-SCLC, as well as in patients with baseline brain metastasis. Moreover, cTRT may be associated with prolonged BMFS, potentially reflecting an abscopal effect. The safety profile remains acceptable, given the substantial survival benefit.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Wróbel D, Wojewoda B, Ziółek W, et al. Consolidative thoracic radiotherapy in the immunotherapy era for extensive-stage small cell lung cancer: a systematic review and meta-analysis with emphasis on brain and liver metastases. Radiother Oncol. 2025. PMID: 41386338. doi:10.1016/j.radonc.2025.111328

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。